50 Cash-Rich Biotech Stocks Being Snapped Up By Hedge Funds
Contextuall | Dec 14, 2012 03:03AM ET
Screen Criteria
Chart: Distribution of 1-Month Returns For All Stocks Mentioned Below
1. Infinity Pharmaceuticals, Inc. (INFI): Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States. Average quarterly operating expense over the last five quarters at $24.72M, vs. most recent cash and short term investments at $188.77M, implies a Cash / Avg. Operating Expense ratio at 7.64.
2. Sequenom Inc. (SQNM): Provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research. Average quarterly operating expense over the last five quarters at $41.71M, vs. most recent cash and short term investments at $193.39M, implies a Cash / Avg. Operating Expense ratio at 4.64.
3. BioSante Pharmaceuticals, Inc. (BPAX): Develops products for female sexual health and oncology. Average quarterly operating expense over the last five quarters at $8.77M, vs. most recent cash and short term investments at $38.05M, implies a Cash / Avg. Operating Expense ratio at 4.34.
4. Amicus Therapeutics, Inc. (FOLD): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Average quarterly operating expense over the last five quarters at $18.6M, vs. most recent cash and short term investments at $106.22M, implies a Cash / Avg. Operating Expense ratio at 5.71.
5. Corcept Therapeutics Incorporated (CORT): Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Average quarterly operating expense over the last five quarters at $8.92M, vs. most recent cash and short term investments at $101.63M, implies a Cash / Avg. Operating Expense ratio at 11.39.
6. Medivation, Inc. (MDVN): Focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer’s disease, and Huntington disease. Average quarterly operating expense over the last five quarters at $39.47M, vs. most recent cash and short term investments at $340.41M, implies a Cash / Avg. Operating Expense ratio at 8.62.
7. Alnylam Pharmaceuticals, Inc. (ALNY): Focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). Average quarterly operating expense over the last five quarters at $33.32M, vs. most recent cash and short term investments at $228.34M, implies a Cash / Avg. Operating Expense ratio at 6.85.
8. Sangamo Biosciences Inc. (SGMO): Engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Average quarterly operating expense over the last five quarters at $10.82M, vs. most recent cash and short term investments at $57.9M, implies a Cash / Avg. Operating Expense ratio at 5.35.
9. Transcept Pharmaceuticals, Inc. (TSPT): Average quarterly operating expense over the last five quarters at $5.87M, vs. most recent cash and short term investments at $98.67M, implies a Cash / Avg. Operating Expense ratio at 16.81.
10. ArQule Inc. (ARQL): Engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Average quarterly operating expense over the last five quarters at $12.85M, vs. most recent cash and short term investments at $82.76M, implies a Cash / Avg. Operating Expense ratio at 6.44.
11. Ariad Pharmaceuticals Inc. (ARIA): Focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. Average quarterly operating expense over the last five quarters at $40.56M, vs. most recent cash and short term investments at $206.66M, implies a Cash / Avg. Operating Expense ratio at 5.1.
12. Cytokinetics, Incorporated (CYTK): Engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Average quarterly operating expense over the last five quarters at $11.82M, vs. most recent cash and short term investments at $75.61M, implies a Cash / Avg. Operating Expense ratio at 6.4.
13. Halozyme Therapeutics, Inc. (HALO): Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. Average quarterly operating expense over the last five quarters at $21.68M, vs. most recent cash and short term investments at $87.61M, implies a Cash / Avg. Operating Expense ratio at 4.04.
14. Xenoport, Inc. (XNPT): Focuses on developing and commercializing internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. Average quarterly operating expense over the last five quarters at $19.34M, vs. most recent cash and short term investments at $112.86M, implies a Cash / Avg. Operating Expense ratio at 5.83.
15. Immunogen Inc. (IMGN): Engages in the research and development of antibody-based anticancer therapeutics in the United States. Average quarterly operating expense over the last five quarters at $23.79M, vs. most recent cash and short term investments at $233.61M, implies a Cash / Avg. Operating Expense ratio at 9.82.
16. Illumina Inc. (ILMN): Develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Average quarterly operating expense over the last five quarters at $223.87M, vs. most recent cash and short term investments at $1233.07M, implies a Cash / Avg. Operating Expense ratio at 5.51.
17. Osiris Therapeutics, Inc. (OSIR): Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. Average quarterly operating expense over the last five quarters at $5.97M, vs. most recent cash and short term investments at $37.22M, implies a Cash / Avg. Operating Expense ratio at 6.24.
18. Onyx Pharmaceuticals, Inc. (ONXX): Engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Average quarterly operating expense over the last five quarters at $116.42M, vs. most recent cash and short term investments at $554.79M, implies a Cash / Avg. Operating Expense ratio at 4.77.
19. Exact Sciences Corporation (EXAS): Focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre-cancer and cancer. Average quarterly operating expense over the last five quarters at $12.31M, vs. most recent cash and short term investments at $118.57M, implies a Cash / Avg. Operating Expense ratio at 9.63.
20. Pain Therapeutics Inc. (PTIE): Engages in the research and development of novel drugs. Average quarterly operating expense over the last five quarters at $3.52M, vs. most recent cash and short term investments at $92.53M, implies a Cash / Avg. Operating Expense ratio at 26.32.
21. Idenix Pharmaceuticals Inc. (IDIX): Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. Average quarterly operating expense over the last five quarters at $22.45M, vs. most recent cash and short term investments at $251.87M, implies a Cash / Avg. Operating Expense ratio at 11.22.
22. Targacept, Inc. (TRGT): Engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. Average quarterly operating expense over the last five quarters at $21.31M, vs. most recent cash and short term investments at $195.61M, implies a Cash / Avg. Operating Expense ratio at 9.18.
23. Geron Corporation (GERN): Develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Average quarterly operating expense over the last five quarters at $21.55M, vs. most recent cash and short term investments at $100.45M, implies a Cash / Avg. Operating Expense ratio at 4.66.
24. Celgene Corporation (CELG): Develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. Average quarterly operating expense over the last five quarters at $866.38M, vs. most recent cash and short term investments at $3832.94M, implies a Cash / Avg. Operating Expense ratio at 4.42.
25. Repros Therapeutics Inc. (RPRX): Average quarterly operating expense over the last five quarters at $3.36M, vs. most recent cash and short term investments at $29.58M, implies a Cash / Avg. Operating Expense ratio at 8.8.
26. Enzon Pharmaceuticals Inc. (ENZN): Engages in the research and development of therapeutics for cancer patients with unmet medical needs. Average quarterly operating expense over the last five quarters at $11.98M, vs. most recent cash and short term investments at $278.44M, implies a Cash / Avg. Operating Expense ratio at 23.23.
27. InterMune Inc. (ITMN): Focuses on developing and commercializing therapies in pulmonology and hepatology. Average quarterly operating expense over the last five quarters at $49.48M, vs. most recent cash and short term investments at $351.4M, implies a Cash / Avg. Operating Expense ratio at 7.1.
28. OncoGenex Pharmaceuticals, Inc. (OGXI): Engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Average quarterly operating expense over the last five quarters at $8.91M, vs. most recent cash and short term investments at $85.07M, implies a Cash / Avg. Operating Expense ratio at 9.55.
29. Amgen Inc. (AMGN): Develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Average quarterly operating expense over the last five quarters at $2917M, vs. most recent cash and short term investments at $25374M, implies a Cash / Avg. Operating Expense ratio at 8.7.
30. Seattle Genetics Inc. (SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Average quarterly operating expense over the last five quarters at $64.52M, vs. most recent cash and short term investments at $313.93M, implies a Cash / Avg. Operating Expense ratio at 4.87.
31. Alexion Pharmaceuticals, Inc. (ALXN): Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Average quarterly operating expense over the last five quarters at $161.43M, vs. most recent cash and short term investments at $905.53M, implies a Cash / Avg. Operating Expense ratio at 5.61.
32. VIVUS Inc. (VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Average quarterly operating expense over the last five quarters at $20.9M, vs. most recent cash and short term investments at $274.48M, implies a Cash / Avg. Operating Expense ratio at 13.13.
33. Arena Pharmaceuticals, Inc. (ARNA): Focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Average quarterly operating expense over the last five quarters at $22.4M, vs. most recent cash and short term investments at $165.77M, implies a Cash / Avg. Operating Expense ratio at 7.4.
34. Curis Inc. (CRIS): Focuses on the research and development of cancer therapeutics. Average quarterly operating expense over the last five quarters at $6.39M, vs. most recent cash and short term investments at $41.14M, implies a Cash / Avg. Operating Expense ratio at 6.44.
35. Sunesis Pharmaceuticals Inc. (SNSS): Focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Average quarterly operating expense over the last five quarters at $9.03M, vs. most recent cash and short term investments at $76.55M, implies a Cash / Avg. Operating Expense ratio at 8.48.
36. Oncothyreon Inc (ONTY): Focuses on the development of therapeutic products for the treatment of cancer. Average quarterly operating expense over the last five quarters at $6.96M, vs. most recent cash and short term investments at $79.16M, implies a Cash / Avg. Operating Expense ratio at 11.37.
37. Threshold Pharmaceuticals Inc. (THLD): Engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Average quarterly operating expense over the last five quarters at $6.76M, vs. most recent cash and short term investments at $65.83M, implies a Cash / Avg. Operating Expense ratio at 9.74.
38. Lexicon Pharmaceuticals, Inc. (LXRX): Focuses on the discovery and development of drug candidates for the treatment of various human diseases. Average quarterly operating expense over the last five quarters at $28.91M, vs. most recent cash and short term investments at $206.42M, implies a Cash / Avg. Operating Expense ratio at 7.14.
39. Achillion Pharmaceuticals, Inc. (ACHN): Engages in the discovery, development, and commercialization of treatments for infectious diseases. Average quarterly operating expense over the last five quarters at $12.32M, vs. most recent cash and short term investments at $80.91M, implies a Cash / Avg. Operating Expense ratio at 6.57.
40. PDL BioPharma, Inc. (PDLI): Engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. Average quarterly operating expense over the last five quarters at $5.3M, vs. most recent cash and short term investments at $160.37M, implies a Cash / Avg. Operating Expense ratio at 30.24.
41. Nektar Therapeutics (NKTR): Engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Average quarterly operating expense over the last five quarters at $51.3M, vs. most recent cash and short term investments at $319.28M, implies a Cash / Avg. Operating Expense ratio at 6.22.
42. Vical Inc. (VICL): Engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Average quarterly operating expense over the last five quarters at $10.05M, vs. most recent cash and short term investments at $86.89M, implies a Cash / Avg. Operating Expense ratio at 8.64.
43. Exelixis, Inc. (EXEL): Engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer, metabolic, and cardiovascular disorders. Average quarterly operating expense over the last five quarters at $42.08M, vs. most recent cash and short term investments at $484.59M, implies a Cash / Avg. Operating Expense ratio at 11.52.
44. Vanda Pharmaceuticals, Inc. (VNDA): Focuses on the development and commercialization of products for the treatment of central nervous system disorders. Average quarterly operating expense over the last five quarters at $14.43M, vs. most recent cash and short term investments at $134.4M, implies a Cash / Avg. Operating Expense ratio at 9.32.
45. Agenus Inc. (AGEN): Develops and commercializes immunotherapies for cancer and infectious diseases. Average quarterly operating expense over the last five quarters at $5.61M, vs. most recent cash and short term investments at $25.46M, implies a Cash / Avg. Operating Expense ratio at 4.54.
46. AVEO Pharmaceuticals, Inc. (AVEO): Engages in the discovery and development of cancer therapeutics. Average quarterly operating expense over the last five quarters at $29.4M, vs. most recent cash and short term investments at $189.69M, implies a Cash / Avg. Operating Expense ratio at 6.45.
47. Insmed Incorporated (INSM): Focuses on the development of inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. Average quarterly operating expense over the last five quarters at $14.45M, vs. most recent cash and short term investments at $89.75M, implies a Cash / Avg. Operating Expense ratio at 6.21.
48. Momenta Pharmaceuticals Inc. (MNTA): Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. Average quarterly operating expense over the last five quarters at $30.37M, vs. most recent cash and short term investments at $361.82M, implies a Cash / Avg. Operating Expense ratio at 11.91.
49. BioSpecifics Technologies Corp. (BSTC): Involves in the development of an injectable collagenase for various indications. Average quarterly operating expense over the last five quarters at $1.47M, vs. most recent cash and short term investments at $9.01M, implies a Cash / Avg. Operating Expense ratio at 6.13.
50. ZIOPHARM Oncology, Inc. (ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Average quarterly operating expense over the last five quarters at $18.99M, vs. most recent cash and short term investments at $95.33M, implies a Cash / Avg. Operating Expense ratio at 5.02.
Get The News You Want
:
List of Biotech stocks that also have significant cash holdings, when compared to quarterly operating expenses.
Average Weekly Returns:
Average 1-Week Return of All Stocks Mentioned Below: 3.18%
Average 1-Month Return of All Stocks Mentioned Below: 7.17%
Analysis of List Alpha:
Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Week): 34 out of 50 (68.0%)
Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Month): 29 out of 50 (58.0%)
Chart: Distribution of 1-Week Returns For All Stocks Mentioned Below
Chart: Distribution of 1-Month Returns For All Stocks Mentioned Below
1. Infinity Pharmaceuticals, Inc. (INFI): Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States. Average quarterly operating expense over the last five quarters at $24.72M, vs. most recent cash and short term investments at $188.77M, implies a Cash / Avg. Operating Expense ratio at 7.64.
2. Sequenom Inc. (SQNM): Provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research. Average quarterly operating expense over the last five quarters at $41.71M, vs. most recent cash and short term investments at $193.39M, implies a Cash / Avg. Operating Expense ratio at 4.64.
3. BioSante Pharmaceuticals, Inc. (BPAX): Develops products for female sexual health and oncology. Average quarterly operating expense over the last five quarters at $8.77M, vs. most recent cash and short term investments at $38.05M, implies a Cash / Avg. Operating Expense ratio at 4.34.
4. Amicus Therapeutics, Inc. (FOLD): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Average quarterly operating expense over the last five quarters at $18.6M, vs. most recent cash and short term investments at $106.22M, implies a Cash / Avg. Operating Expense ratio at 5.71.
5. Corcept Therapeutics Incorporated (CORT): Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Average quarterly operating expense over the last five quarters at $8.92M, vs. most recent cash and short term investments at $101.63M, implies a Cash / Avg. Operating Expense ratio at 11.39.
6. Medivation, Inc. (MDVN): Focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer’s disease, and Huntington disease. Average quarterly operating expense over the last five quarters at $39.47M, vs. most recent cash and short term investments at $340.41M, implies a Cash / Avg. Operating Expense ratio at 8.62.
7. Alnylam Pharmaceuticals, Inc. (ALNY): Focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). Average quarterly operating expense over the last five quarters at $33.32M, vs. most recent cash and short term investments at $228.34M, implies a Cash / Avg. Operating Expense ratio at 6.85.
8. Sangamo Biosciences Inc. (SGMO): Engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Average quarterly operating expense over the last five quarters at $10.82M, vs. most recent cash and short term investments at $57.9M, implies a Cash / Avg. Operating Expense ratio at 5.35.
9. Transcept Pharmaceuticals, Inc. (TSPT): Average quarterly operating expense over the last five quarters at $5.87M, vs. most recent cash and short term investments at $98.67M, implies a Cash / Avg. Operating Expense ratio at 16.81.
10. ArQule Inc. (ARQL): Engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Average quarterly operating expense over the last five quarters at $12.85M, vs. most recent cash and short term investments at $82.76M, implies a Cash / Avg. Operating Expense ratio at 6.44.
11. Ariad Pharmaceuticals Inc. (ARIA): Focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. Average quarterly operating expense over the last five quarters at $40.56M, vs. most recent cash and short term investments at $206.66M, implies a Cash / Avg. Operating Expense ratio at 5.1.
12. Cytokinetics, Incorporated (CYTK): Engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Average quarterly operating expense over the last five quarters at $11.82M, vs. most recent cash and short term investments at $75.61M, implies a Cash / Avg. Operating Expense ratio at 6.4.
13. Halozyme Therapeutics, Inc. (HALO): Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. Average quarterly operating expense over the last five quarters at $21.68M, vs. most recent cash and short term investments at $87.61M, implies a Cash / Avg. Operating Expense ratio at 4.04.
14. Xenoport, Inc. (XNPT): Focuses on developing and commercializing internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to enhance the therapeutic benefits of drugs. Average quarterly operating expense over the last five quarters at $19.34M, vs. most recent cash and short term investments at $112.86M, implies a Cash / Avg. Operating Expense ratio at 5.83.
15. Immunogen Inc. (IMGN): Engages in the research and development of antibody-based anticancer therapeutics in the United States. Average quarterly operating expense over the last five quarters at $23.79M, vs. most recent cash and short term investments at $233.61M, implies a Cash / Avg. Operating Expense ratio at 9.82.
16. Illumina Inc. (ILMN): Develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Average quarterly operating expense over the last five quarters at $223.87M, vs. most recent cash and short term investments at $1233.07M, implies a Cash / Avg. Operating Expense ratio at 5.51.
17. Osiris Therapeutics, Inc. (OSIR): Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. Average quarterly operating expense over the last five quarters at $5.97M, vs. most recent cash and short term investments at $37.22M, implies a Cash / Avg. Operating Expense ratio at 6.24.
18. Onyx Pharmaceuticals, Inc. (ONXX): Engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Average quarterly operating expense over the last five quarters at $116.42M, vs. most recent cash and short term investments at $554.79M, implies a Cash / Avg. Operating Expense ratio at 4.77.
19. Exact Sciences Corporation (EXAS): Focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre-cancer and cancer. Average quarterly operating expense over the last five quarters at $12.31M, vs. most recent cash and short term investments at $118.57M, implies a Cash / Avg. Operating Expense ratio at 9.63.
20. Pain Therapeutics Inc. (PTIE): Engages in the research and development of novel drugs. Average quarterly operating expense over the last five quarters at $3.52M, vs. most recent cash and short term investments at $92.53M, implies a Cash / Avg. Operating Expense ratio at 26.32.
21. Idenix Pharmaceuticals Inc. (IDIX): Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. Average quarterly operating expense over the last five quarters at $22.45M, vs. most recent cash and short term investments at $251.87M, implies a Cash / Avg. Operating Expense ratio at 11.22.
22. Targacept, Inc. (TRGT): Engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. Average quarterly operating expense over the last five quarters at $21.31M, vs. most recent cash and short term investments at $195.61M, implies a Cash / Avg. Operating Expense ratio at 9.18.
23. Geron Corporation (GERN): Develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Average quarterly operating expense over the last five quarters at $21.55M, vs. most recent cash and short term investments at $100.45M, implies a Cash / Avg. Operating Expense ratio at 4.66.
24. Celgene Corporation (CELG): Develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. Average quarterly operating expense over the last five quarters at $866.38M, vs. most recent cash and short term investments at $3832.94M, implies a Cash / Avg. Operating Expense ratio at 4.42.
25. Repros Therapeutics Inc. (RPRX): Average quarterly operating expense over the last five quarters at $3.36M, vs. most recent cash and short term investments at $29.58M, implies a Cash / Avg. Operating Expense ratio at 8.8.
26. Enzon Pharmaceuticals Inc. (ENZN): Engages in the research and development of therapeutics for cancer patients with unmet medical needs. Average quarterly operating expense over the last five quarters at $11.98M, vs. most recent cash and short term investments at $278.44M, implies a Cash / Avg. Operating Expense ratio at 23.23.
27. InterMune Inc. (ITMN): Focuses on developing and commercializing therapies in pulmonology and hepatology. Average quarterly operating expense over the last five quarters at $49.48M, vs. most recent cash and short term investments at $351.4M, implies a Cash / Avg. Operating Expense ratio at 7.1.
28. OncoGenex Pharmaceuticals, Inc. (OGXI): Engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. Average quarterly operating expense over the last five quarters at $8.91M, vs. most recent cash and short term investments at $85.07M, implies a Cash / Avg. Operating Expense ratio at 9.55.
29. Amgen Inc. (AMGN): Develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Average quarterly operating expense over the last five quarters at $2917M, vs. most recent cash and short term investments at $25374M, implies a Cash / Avg. Operating Expense ratio at 8.7.
30. Seattle Genetics Inc. (SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Average quarterly operating expense over the last five quarters at $64.52M, vs. most recent cash and short term investments at $313.93M, implies a Cash / Avg. Operating Expense ratio at 4.87.
31. Alexion Pharmaceuticals, Inc. (ALXN): Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Average quarterly operating expense over the last five quarters at $161.43M, vs. most recent cash and short term investments at $905.53M, implies a Cash / Avg. Operating Expense ratio at 5.61.
32. VIVUS Inc. (VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Average quarterly operating expense over the last five quarters at $20.9M, vs. most recent cash and short term investments at $274.48M, implies a Cash / Avg. Operating Expense ratio at 13.13.
33. Arena Pharmaceuticals, Inc. (ARNA): Focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Average quarterly operating expense over the last five quarters at $22.4M, vs. most recent cash and short term investments at $165.77M, implies a Cash / Avg. Operating Expense ratio at 7.4.
34. Curis Inc. (CRIS): Focuses on the research and development of cancer therapeutics. Average quarterly operating expense over the last five quarters at $6.39M, vs. most recent cash and short term investments at $41.14M, implies a Cash / Avg. Operating Expense ratio at 6.44.
35. Sunesis Pharmaceuticals Inc. (SNSS): Focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Average quarterly operating expense over the last five quarters at $9.03M, vs. most recent cash and short term investments at $76.55M, implies a Cash / Avg. Operating Expense ratio at 8.48.
36. Oncothyreon Inc (ONTY): Focuses on the development of therapeutic products for the treatment of cancer. Average quarterly operating expense over the last five quarters at $6.96M, vs. most recent cash and short term investments at $79.16M, implies a Cash / Avg. Operating Expense ratio at 11.37.
37. Threshold Pharmaceuticals Inc. (THLD): Engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Average quarterly operating expense over the last five quarters at $6.76M, vs. most recent cash and short term investments at $65.83M, implies a Cash / Avg. Operating Expense ratio at 9.74.
38. Lexicon Pharmaceuticals, Inc. (LXRX): Focuses on the discovery and development of drug candidates for the treatment of various human diseases. Average quarterly operating expense over the last five quarters at $28.91M, vs. most recent cash and short term investments at $206.42M, implies a Cash / Avg. Operating Expense ratio at 7.14.
39. Achillion Pharmaceuticals, Inc. (ACHN): Engages in the discovery, development, and commercialization of treatments for infectious diseases. Average quarterly operating expense over the last five quarters at $12.32M, vs. most recent cash and short term investments at $80.91M, implies a Cash / Avg. Operating Expense ratio at 6.57.
40. PDL BioPharma, Inc. (PDLI): Engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. Average quarterly operating expense over the last five quarters at $5.3M, vs. most recent cash and short term investments at $160.37M, implies a Cash / Avg. Operating Expense ratio at 30.24.
41. Nektar Therapeutics (NKTR): Engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Average quarterly operating expense over the last five quarters at $51.3M, vs. most recent cash and short term investments at $319.28M, implies a Cash / Avg. Operating Expense ratio at 6.22.
42. Vical Inc. (VICL): Engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Average quarterly operating expense over the last five quarters at $10.05M, vs. most recent cash and short term investments at $86.89M, implies a Cash / Avg. Operating Expense ratio at 8.64.
43. Exelixis, Inc. (EXEL): Engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer, metabolic, and cardiovascular disorders. Average quarterly operating expense over the last five quarters at $42.08M, vs. most recent cash and short term investments at $484.59M, implies a Cash / Avg. Operating Expense ratio at 11.52.
44. Vanda Pharmaceuticals, Inc. (VNDA): Focuses on the development and commercialization of products for the treatment of central nervous system disorders. Average quarterly operating expense over the last five quarters at $14.43M, vs. most recent cash and short term investments at $134.4M, implies a Cash / Avg. Operating Expense ratio at 9.32.
45. Agenus Inc. (AGEN): Develops and commercializes immunotherapies for cancer and infectious diseases. Average quarterly operating expense over the last five quarters at $5.61M, vs. most recent cash and short term investments at $25.46M, implies a Cash / Avg. Operating Expense ratio at 4.54.
46. AVEO Pharmaceuticals, Inc. (AVEO): Engages in the discovery and development of cancer therapeutics. Average quarterly operating expense over the last five quarters at $29.4M, vs. most recent cash and short term investments at $189.69M, implies a Cash / Avg. Operating Expense ratio at 6.45.
47. Insmed Incorporated (INSM): Focuses on the development of inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. Average quarterly operating expense over the last five quarters at $14.45M, vs. most recent cash and short term investments at $89.75M, implies a Cash / Avg. Operating Expense ratio at 6.21.
48. Momenta Pharmaceuticals Inc. (MNTA): Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. Average quarterly operating expense over the last five quarters at $30.37M, vs. most recent cash and short term investments at $361.82M, implies a Cash / Avg. Operating Expense ratio at 11.91.
49. BioSpecifics Technologies Corp. (BSTC): Involves in the development of an injectable collagenase for various indications. Average quarterly operating expense over the last five quarters at $1.47M, vs. most recent cash and short term investments at $9.01M, implies a Cash / Avg. Operating Expense ratio at 6.13.
50. ZIOPHARM Oncology, Inc. (ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Average quarterly operating expense over the last five quarters at $18.99M, vs. most recent cash and short term investments at $95.33M, implies a Cash / Avg. Operating Expense ratio at 5.02.
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.